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Abstract
Mechanisms for breast cancer metastasis remain unclear. Whether truncated glioma-associated 
oncogene homolog 1 (TGLI1), a transcription factor known to promote angiogenesis, migration 
and invasion, plays any role in metastasis of any tumor type has never been investigated. In this 
study, results of two mouse models of breast cancer metastasis showed that ectopic expression of 
TGLI1, but not GLI1, promoted preferential metastasis to the brain. Conversely, selective TGLI1 
knockdown using antisense oligonucleotides led to decreased breast cancer brain metastasis 
(BCBM) in vivo. Immunohistochemical staining showed that TGLI1, but not GLI1, was increased 
in lymph node metastases compared to matched primary tumors, and that TGLI1 was expressed at 
higher levels in BCBM specimens compared to primary tumors. TGLI1 activation is associated 
with a shortened time to develop BCBM and enriched in HER2-enriched and triple-negative breast 
cancers. Radioresistant BCBM cell lines and specimens expressed higher levels of TGLI1, but not 
GLI1, than radiosensitive counterparts. Since cancer stem cells (CSCs) are radioresistant and 
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metastasis-initiating cells, we examined TGLI1 for its involvement in breast CSCs and found 
TGLI1 to transcriptionally activate stemness genes CD44, Nanog, Sox2, and OCT4 leading to 
CSC renewal, and TGLI1 outcompetes with GLI1 for binding to target promoters. We next 
examined whether astrocyte-priming underlies TGLI1-mediated brain tropism and found that 
TGLI1-positive CSCs strongly activated and interacted with astrocytes in vitro and in vivo. These 
findings demonstrate, for the first time, that TGLI1 mediates breast cancer metastasis to the brain, 
in part, through promoting metastasis-initiating CSCs and activating astrocytes in BCBM 
microenvironment.
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INTRODUCTION
Breast cancer is the second leading cause of cancer-related mortality in women and 
metastasis to distant organs result in 90% of breast cancer deaths1. Metastatic breast cancers 
occur in 20–30% of cases with a 5-year survival rate of 22%2. The most common sites of 
breast cancer metastases are bone, lung, brain, and liver. HER2-enriched and triple-negative 
breast cancer (TNBC) subtypes have the highest propensity to metastasize to the brain, 
ranging from 20–30% in HER2 and 45–60% in TNBC2. Breast cancer brain metastasis 
(BCBM) constitutes ~10–30% of metastatic breast cancer cases3. Current therapeutic 
options for women with BCBM include whole brain radiotherapy, surgical resection, and 
stereotactic radiosurgery4. Despite our current therapies and understanding of BCBM, breast 
cancer patients with brain metastases have a dismal prognosis of only 6–18 months of 
survival following diagnosis3. Mechanisms underlying BCBM remain poorly understood.
Our laboratory discovered a truncated form of glioma-associated oncogene homolog 1 
(TGLI1 or tGLI1) and we have demonstrated that it is a gain-of-function GLI1 zinc-finger 
transcription factor5–10. TGLI1 is an alternatively spliced variant of GLI1, as a result of a 41 
amino acid in-frame deletion, which retains all of the functional domains as GLI1, and is 
activated by the Shh-PTCH1-SMO signaling axis8. We have shown that TGLI1 is expressed 
in GBM and breast cancer, but is not expressed in normal brain or breast tissue5, 8, 9, 11. 
Consistent with our findings, TGLI1 was reported to be expressed in highly invasive 
hepatocellular carcinoma but is not detected in normal hepatocytes12. TGLI1 has the ability 
to regulate GLI1 target genes but gains the ability to upregulate seven target genes which are 
not regulated by GLI15–10, namely, VEGF-A, VEGF-C, VEGFR2, TEM7, HPSE, CD24, 
and CD44 resulting in increased growth, angiogenesis, migration and invasion of glioma 
cells in vivo and breast cancer cells in vitro. In line with our results, VEGFR2 was reported 
to be transcriptionally activated by TGLI1 in TNBC cells leading to increased 
angiogenesis13. Whether TGLI1 plays any role in metastasis for any tumor type has never 
been investigated.
In this study, we aimed to determine whether TGLI1 plays a role in breast cancer metastasis. 
Through the use of three in vivo mouse models of metastasis, we observed that TGLI1 
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promotes BCBM and facilitates the intracranial growth of breast cancer cells. We further 
observed that TGLI1 activation correlates with shortened metastasis-free survival and that 
TGLI1 expression is enriched in BCBM patient samples. Moreover, we found TGLI1 to play 
an important role in radioresistance and cancer stem cells (CSCs), through upregulating 
stemness gene expression and that TGLI1 outcompetes GLI1 for binding to target gene 
promoters. In agreement with an important role for astrocytes in intracranial tumor growth, 
TGLI1-positive CSCs strongly activate and interact with astrocytes and TGLI1-positive 
BCBM tumors strongly activate astrocytes in mouse brain. Lastly, knockdown of TGLI1 led 
to decreased cancer stemness in vitro and reduced BCBM in vivo. Collectively, our study 
defined TGLI1 as a novel mediator of BCBM, breast CSCs, activation of astrocytes in 
BCBM microenvironment, and resistance to radiation therapy.
MATERIALS AND METHODS
Cell lines, tumor specimens, and expression plasmids
Human breast cancer cell lines MCF10A, MCF7, and BT20 were purchased from ATCC 
(Manassas, VA) and cultured as specified by ATCC. HMLE, MDA-MB-231, and brain 
metastatic MDA-MB-231-BRM cell lines are from the Weinberg and Massagué laboratories, 
respectively. The brain metastatic cell line (SKBRM), radio-resistant cell lines (SKBRM-RR 
and 231BRM-RR), and E6/E7/hTERT immortalized human astrocytes were kind gifts from 
Drs. Fei Xing and Kounosuke Watabe. BC tissue microarrays (BR10010, BR952, BC01116) 
were purchased from US Biomax (Rockville, MD). BCBM patient specimens are from the 
Wake Forest Tumor Tissue Core and Dr. Kounosuke Watabe. The expression plasmids for 
GLI1 and TGLI1 were previously developed in our laboratory8.
Animal studies
All animal experiments were conducted as approved by the Wake Forest Institutional 
Animal Care and Use Committee. Isogenic MDA231 lines with vector, GLI1, or TGLI1, and 
SKBRM with negative control oligos or TGLI1-AS-ON (1×105 cells) were injected into the 
left cardiac ventricle of female nu/nu mice and monitored bi-weekly using an In Vivo 
Imaging System (IVIS). Intracranial implantations were performed as we described 
previously9. Briefly, female nu/nu mice were anesthetized with ketamine/xylazine and 
isogenic cells (2×104 cells/5 uL PBS) were stereotactically implanted into the right frontal 
lobe of the brain. Mice were monitored weekly using IVIS.
Selective knockdowns of GLI1 and TGLI1
Control or TGLI1 specific locked nucleic acid (LNA) antisense oligonucleotides (AS-ON) 
were custom designed and purchased from Qiagen. Knockdown of TGLI1 was conducted as 
described previously9. Briefly, BT20 or SKBRM cells were transfected for 48 hours with 
control or TGLI1 AS-ON using Lipofectamine 2000 (Invitrogen) and then cells were 
harvested for qRT-PCR, seeded for mammosphere assay, or intracardially injected into 
female nu/nu mice described above.
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Statistical analyses
Results are represented as ± SE. One-way ANOVA, Fisher’s Exact Test, Log-Rank test, and 
student’s t-test were performed using GraphPad Prism 5.
RESULTS
TGLI1 promotes brain metastasis of TNBC in an intracardiac injection metastasis mouse 
model
A role of TGLI1 in metastasis in any tumor type has not been investigated. To determine the 
effects of TGLI1 on metastasis, we generated isogenic TNBC MDA-MB-231 cell lines to 
overexpress TGLI1, GLI1 or control vector using lentiviral constructs9 and the firefly 
luciferase reporter. Stable expression of TGLI1 or GLI1 was confirmed using western 
blotting (Fig. 1A). Exogenous GLI1 and TGLI1 were expressed at physiologically relevant 
levels as indicated by comparable levels of GLI1 and TGLI1 in mammary fat pad (MFP) 
xenografts and primary breast carcinoma samples (Fig. 1B). Immunohistochemistry was 
conducted using TGLI1- and GLI1-specific antibodies we previously developed and 
validated6, 7, 9, 10. Of note, commercially available GLI1 antibodies detect both GLI1 and 
TGLI1 isoforms. Expression of TGLI1 in MDA-231-TGLI1 MFP tumor was equivalent to 
that detected in breast cancer PDXs as indicated by western blots (Fig. 1C); BCM-2174 
(TNBC) and BCM-3963 (HER2-enriched) PDXs were shown to undergo brain metastasis14. 
We next used an experimental metastasis model to mimic several stages of metastasis 
including evasion of anoikis, intravasation, and colonization to distant organs, mainly to the 
brain and bone. For this, the isogenic lines were injected into the left ventricle of athymic 
female mice and the mice were imaged biweekly using an In Vivo Imaging System (IVIS). 
Representative bioluminescent images showed TGLI1 preferentially increased breast cancer 
metastasis to the brain compared to GLI1 and vector groups (Fig. 1D). To confirm 
bioluminescent signals were strictly from the brain or bone, but not surrounding tissues, we 
imaged the brain and bones ex vivo and we observed TGLI1 mice to have increased brain 
metastasis (Fig. 1E–G), but reduced bone metastasis compared to the vector group (Fig. 1F–
G). We further found the TGLI1 group to have the greater number of tumor foci among the 
three groups (Fig. 1H–I). These results suggest that TGLI1 promotes brain metastasis of 
circulating breast cancer cells.
TGLI1 promotes the growth of TNBC in mouse brain in an intracranial injection mouse 
model
We next evaluated the effects of TGLI1 on breast cancer intracranial growth using an 
intracranial implantation model. The isogenic MDA-MB-231 cell lines were implanted into 
the brain of female athymic mice and imaged weekly. The results showed TGLI1-expressing 
breast cancer cells were more tumorigenic than those with vector or GLI1 (Fig. 2A–B). 
TGLI1-positive brain metastases were significantly larger than GLI1 and vector tumors (Fig. 
2C). Mouse brains carrying TGLI1-expressing BCBM were visibly larger and highly 
vascularized (Fig. 2D). We next examined tumors for expression of GLI1 and TGLI1 via 
immunohistochemistry (IHC), and confirmed their expression (Fig. 2E). TGLI1-expressing 
BCBM were more invasive as indicated by the hematoxylin and eosin (H&E) staining, more 
vascularized (CD31 IHC; Fig. 2F), and more proliferative (Ki-67 IHC; Fig. 2G) compared to 
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vector and GLI1 xenografts. These results indicate that TGLI1 promotes intracranial growth, 
invasion and angiogenesis of TNBC cells.
Activation of TGLI1 is enriched in HER2-enriched and triple-negative breast cancers and 
associated with poor metastasis-free survival
Whether TGLI1 target genes are associated with breast cancer patient outcomes remains 
unknown. DNA microarray probes do not distinguish TGLI1 from GLI1 transcripts. 
Therefore, we generated a TGLI1 activation signature (tGAS-6) containing six validated 
TGLI1 target genes (VEGFA, VEGFC, VEGFR2, TEM7, HPSE, and CD24) known to be 
regulated by TGLI1 but not GLI15–8, 14 and determined whether tGAS-6 is correlated with 
patient survival using two large datasets retrieved from The Cancer Genome Atlas (TCGA) 
and Gene Expression Omnibus (GEO). The cDNA microarray probes used for GLI1 
expression in both platforms detect both GLI1 and TGLI1 together. We found that TGLI1 is 
activated to a higher extent in HER2 and TNBC subtypes compared to luminal A/B subtypes 
in both TCGA and GEO datasets, whereas GLI1/TGLI1 expression was decreased in both 
datasets (Fig. 3A–B). Kaplan-Meier analysis of the GEO dataset indicated that patients with 
high tGAS-6, but not high GLI1/TGLI1 expression, had shortened overall metastasis-free 
survival (MFS; Fig. 3C), shortened brain MFS (Fig. 3D), and shortened lung and bone MFS 
(Supplementary Fig. 1A–B). These results indicated that TGLI1 activation is common in 
HER2-enriched breast cancer and TNBC, and associated with poor MFS, including brain 
MFS.
Expression of TGLI1 is increased in lymph node metastases and BCBM samples 
compared to primary breast carcinomas
A systematic analysis for TGLI1 expression, in comparison to GLI1, of breast cancer 
specimens has not been carried out. Analysis of primary breast carcinomas for TGLI1 and 
GLI1 protein expression by IHC indicated that TGLI1 expression was significantly higher in 
lymph node-positive, LN(+), primary breast tumors compared to LN(−) tumors, and that in 
LN(+) tumors, TGLI1 levels were higher than GLI1 expression (Fig. 3E). Furthermore, we 
immunostained 47 pairs of primary breast carcinomas and their matched LN metastases and 
found that TGLI1 expression was higher in LN metastases than in matched primary tumors 
and that TGLI1 levels were higher than GLI1 expression in both primary tumors and LN 
metastases (Fig. 3F–G). As shown in Supplementary Fig. 1C, GLI1 expression is higher in 
the paired lymph node metastases compared to the primary tumor but this trend was seen in 
66% of the matched pairs and approximately 32% of the matched pairs have decreased GLI1 
expression. TGLI1 expression was higher than GLI1 in LN(+) breast cancer in a pairwise 
analysis (N=57; Fig. 3H). Next, we analyzed 37 BCBM specimens via IHC and compared 
their TGLI1/GLI1 expression levels to those in primary breast tumors; the results showed 
that TGLI1 levels were higher in BCBM than primary tumors (Fig. 3I). Pairwise analysis 
showed that in BCBM, TGLI1 was expressed at higher levels than GLI1 (Fig. 3J–K). These 
results showed that TGLI1 expression is increased in LN metastases and BCBM samples 
compared to primary breast carcinomas, suggesting its important role in BCBM.
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TGLI1 contributes to BCBM radioresistance
Standard treatment modalities for patients with BCBM include surgical resection, whole 
brain radiotherapy, and stereotactic radiosurgery4. Whether TGLI1 has any effect on 
radioresistance for any tumor type has never been investigated. Here, we evaluated the 
expression levels of TGLI1 and GLI1 in HER2-enriched brain-trophic (SKBRM) cells 
treated with 0, 2, or 5 Gray (Gy) of radiation. As shown in Fig. 4A, TGLI1 expression was 
significantly induced by radiation in a dose-dependent fashion whereas GLI1 expression was 
not significantly altered. We further observed that TGLI1 was expressed at higher levels in 
radioresistant SKBRM (SKBRM-RR) and MDA-MB-231-BrM (231BRM-RR) cells than 
the radiosensitive parental lines (Fig. 4B), whereas GLI1 levels were reduced in the 
radioresistant lines (Fig. 4C). Since radioresistance is an intrinsic hallmark of CSCs and the 
Hh pathway is an important mediator of tumorigenesis and stemness15, we determined 
whether TGLI1 contributes to the radioresistant phenotype of breast CSCs. We grew 
SKBRM-RR and SKBRM cells as mammospheres and evaluated levels of TGLI1; results 
showed that TGLI1 was expressed at higher levels in SKBRM-RR mammospheres than 
SKBRM mammospheres, whereas GLI1 expression was significantly decreased (Fig. 4D). 
Further shown in Fig. 4E–F, we observed that TGLI1 overexpression rendered radiosensitive 
stem cells (mammosphere) resistant to irradiation, and radioresistant stem cells were more 
resistant to irradiation. Furthermore, we confirmed these findings using 20 radiosensitive 
and 16 radioresistant BCBM samples by IHC. Radiosensitive samples were from patients 
that did not have recurrence one year after gamma-knife radiosurgery whereas radioresistant 
BCBMs were from patients with recurrence within one year of gamma-knife treatment. As 
shown in Fig. 4G–I, TGLI1 expression was significantly higher in radioresistant BCBMs 
than in radiosensitive samples whereas GLI1 was not differentially expressed between the 
two groups. Collectively, these data suggest a novel role that TGLI1 plays in radioresistance 
of BCBM.
TGLI1 promotes breast CSCs; TGLI1-positive stem cells activate human astrocytes
To elucidate the mechanism by which TGLI1 mediates BCBM and radioresistance, we 
examined the effects of TGLI1 on breast CSCs as they are resistant to radiation and are 
considered the metastasis-initiating cells16. Here, we determined TGLI1 expression levels in 
monolayer versus mammosphere (stem cell population) culture, and found TGLI1 to be 
induced by mammosphere culture in three different breast cancer cell lines, including 
luminal A (MCF-7), TNBC basal (BT-20), and brain-trophic HER2-enriched (SKBRM; Fig. 
5A–B). As shown in Supplementary Fig. 2A, TGLI1 expression in monolayer was not 
induced by mammosphere media, indicating TGLI1 induction was due to CSCs and not 
growth factors present in the media. Furthermore, TGLI1 overexpression in MDA-MB-231 
cells led to increased stem cell population defined by CD44high/CD24low (Fig. 5C). Ectopic 
expression of TGLI1 enhanced the mammosphere-forming ability of BT-20 cells (Fig. 5D–
F), SKBRM cells (Fig. 5G–I), and promoted mammosphere-forming ability of two 
immortalized normal mammary epithelial cell lines, MCF10A and HMLE (Supplementary 
Fig. 2B–C), and enhanced the anchorage-independent growth of HMLE cells 
(Supplementary Fig. 2D).
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Reactive astrocytes have been shown to support the arrest, extravasation, and growth of 
breast cancer cells in the brain17. To explore whether TGLI1-expressing breast CSCs have 
any effect on astrocyte activation, we stimulated human astrocytes with conditioned medium 
from SKBRM cells grown in monolayer or mammosphere culture. As shown in Fig. 5J–K, 
TGLI1-positive mammospheres significantly activated astrocytes as indicated by increased 
glial fibrillary acidic protein (GFAP) expression. Further shown in Fig. 5L, astrocytes only 
survived and interacted with TGLI1-positive breast CSCs under the sphere-forming stem 
cell culturing condition. Immunostaining of mouse BCBM tumors (described in Fig. 2) 
revealed TGLI1-positive tumors significantly activated astrocytes in vivo (Fig. 5M–N). In 
contrast, no difference was observed between vector and GLI1 groups. Together, these 
results indicated that TGLI1 promotes breast CSCs and that TGLI1-positive stem cells and 
tumors can activate astrocytes in vitro and in vivo respectively, a mechanism underlying 
TGLI1-mediated brain metastasis.
TGLI1 upregulates stemness genes in breast cancer cells
Whether TGLI1 transcriptionally regulates stemness genes in breast cancer has never been 
investigated. Here, we determined the extent to which TGLI1 mediates breast CSCs by 
examining the ability of TGLI1 to regulate expression of four genes that are important for 
pluripotency and stem cell self-renewal, namely, Nanog, SOX2, OCT4, and CD4418, 19. 
GLI1 has been previously shown to directly regulate expression of SOX2 and Nanog20, 21. 
We recently reported that TGLI1, but not GLI1, transcriptionally upregulated CD44 gene 
expression in glioma stem cells9. Whether OCT4 can be regulated by TGLI1 has not been 
reported. To identify whether these genes are associated with BCBM, we used Kaplan-Meier 
analysis and the same GEO datasets used in Fig. 3C–D, and found that SOX2 and OCT4, but 
not Nanog and CD44, were associated with shortened brain MFS (Supplementary Fig. 3A). 
We found that TGLI1 upregulates expression of all four stemness genes (Fig. 6A–C & 
Supplementary Fig. 3B–D). Of note, Nanog, SOX2, and OCT4 were significantly 
upregulated by TGLI1 in comparison to both vector and GLI1 in three cell lines. Consistent 
with the mRNA results, protein levels of all four stemness genes were enhanced by TGLI1 
in SKBRM cells (Fig. 6D). We next examined whether TGLI1 regulates expression of GLI2 
target genes22–24 and found TGLI1 to upregulate GLI2 target genes to a higher extent than 
GLI1 (Supplementary Fig. 3E). Promoter luciferase reporter assay showed that TGLI1 
possessed the ability to transactivate the promoters of Nanog and SOX2 (two known GLI1 
target genes; Fig. 6E–F). Using chromatin immunoprecipitation (ChIP) and promoter 
luciferase reporter assays, we further found that TGLI1 significantly bound to and 
transactivated CD44 (Fig. 6G–H) and OCT4 (Fig. 6I–J) promoters. Interestingly, we found 
that TGLI1 bound to the OCT4 promoter to a similar degree as GLI1; however, TGLI1 was 
able to transactivate the OCT4 promoter more than GLI1 to increase OCT4 mRNA and 
protein expression. Although GLI family of proteins do not dimerize with each other, we 
determined whether TGLI1 and GLI1 compete to bind to target gene promoters. We used 
isogenic MDA-MB-231 cells overexpressing both GLI1 and TGLI1, and performed ChIP 
assay using TGLI1- and GLI1-specific antibodies. As shown in Fig. 6K, TGLI1 
preferentially binds to the OCT4 promoter in the presence of GLI1, indicating that TGLI1 
outcompetes GLI1 for binding to target gene promoters. Collectively, these results 
demonstrate that TGLI1 is a gain-of-function GLI1 transcription factor with the ability to 
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upregulate stemness genes and that TGLI1 is a novel transcriptional activator of Nanog, 
SOX2, and OCT4.
Eight-gene TGLI1 activation signature (tGAS-8) is predictive of breast cancer metastasis 
and radioresistance
We recently identified two new TGLI1 target genes, CD44 and OCT4, which prompted us to 
create the 8-gene TGLI1 activation signature (tGAS-8) and determine its utility as a 
prognostic marker for breast cancer metastasis. Using tGAS-8 and the GEO datasets used 
earlier in Fig. 3, we found that tGAS-8 was more enriched in the HER2 and TNBC subtypes 
than the luminal A/B subtypes (Supplementary Fig. 3F). Metastatic breast tumors had higher 
tGAS-8 than non-metastatic counterparts (Fig. 6L & Supplementary Fig. 3G). Patients with 
brain or lung metastases had higher tGAS-8 in their primary tumors compared to those with 
bone metastases and no metastases (Supplementary Fig. 3H). In contrast, GLI1/TGLI1 
mRNA was decreased in breast cancer with metastases (Supplementary Fig. 3G–H). 
Furthermore, Kaplan-Meier analyses showed that patients with high tGAS-8 have a 
shortened overall MFS, as well as, shortened brain, lung, and bone MFS, compared to those 
with low tGAS-8 (Fig. 6M & Supplementary Fig. 3I). Next, we investigated whether 
tGAS-8 is associated with metastasis and radioresistance using Gene Set Enrichment 
Analysis (GSEA) and the same GEO datasets. For this, we retrieved previously established 
signatures for cancer metastasis25, BCBM26, 27, EMT28, breast cancer stemness29, and 
breast cancer radioresistance30 (Fig. 6N & Supplemental Fig. 3J–M). The results showed 
that breast tumors with high tGAS-8, but not GLI1/TGLI1 mRNA, were enriched for all five 
signatures. Taken together, these results indicated that tGAS-8 can be used as a prognostic 
indicator for metastatic breast cancer and radioresistance.
TGLI1 Knockdown suppresses breast CSCs in vitro and reduces BCBM in vivo
To further validate the effects of TGLI1 on breast CSCs, we used validated antisense 
oligonucleotides (AS-ON) to selectively knockdown TGLI1 in BT20 and SKRBM cells then 
determined the effect on mammosphere-forming ability. Consistent with our recent report9 
the AS-ON led to selective knockdown of TGLI1 in both cell lines and significantly 
decreased the number of mammospheres compared to control (Fig. 7A–B). TGLI1 
knockdown decreased expression of the recently identified TGLI1 target genes, OCT4 and 
CD44 (Fig. 7C). To determine the functional role of TGLI1 on breast cancer metastasis, we 
knocked down TGLI1 in brain trophic SKBRM cells and performed intracardiac injections 
to study brain and bone metastasis (Fig. 7D). Ex vivo analysis of the brain and bone revealed 
a significant decrease in brain metastases in the TGLI1 knockdown group (Fig. 7E–F) but no 
difference in bone metastases (Fig. 7E–G). These results further support the novel role of 
TGLI1 in mediating breast cancer stem cells and BCBM.
DISCUSSION
In this study we made the following novel and impactful observations: (1) TGLI1 promotes 
breast cancer metastasis to brain, and intracranial growth of breast cancer cells in two mouse 
models of breast cancer metastasis; (2) TGLI1 activation is increased in HER2-enriched and 
TNBC subtypes and is associated with shortened brain MFS; (3) TGLI1 expression is 
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enriched in LN metastases and BCBM specimens compared to primary breast carcinomas; 
(4) TGLI1 is increased in radioresistant BCBM cell lines and specimens compared to 
radiosensitive counterparts, and contributes to resistance of BCBM cells; (5) TGLI1 
promotes mammosphere formation in breast cancer cells and normal mammary epithelial 
cells; (6) TGLI1 mediates breast CSCs by transcriptionally activating cancer stemness gene 
expression; (7) TGLI1 upregulates expression of GLI2 target genes; (8) TGLI1 outcompetes 
with GLI1 to bind to OCT4 gene promoter; (9) TGLI1-postive breast CSCs strongly activate 
and interact with astrocytes in vitro and in vivo; and (10) TGLI1 knockdown decreases 
mammosphere formation, decreases stemness gene expression, and reduces breast cancer 
metastasis to the brain. Through making these significant observations, our study defines 
TGLI1 as a novel mediator of brain metastasis, astrocyte activation, and resistance to 
radiation therapy in breast cancer, thereby providing novel insights into the molecular 
mechanisms for BCBM.
We observed in this study that TGLI1 promotes breast CSCs. This is consistent with 
previous studies reporting that a subpopulation of breast CSCs can be characterized by cell-
surface expression of CD44high/CD24low 31, 32. Interestingly, we have previously reported 
that both CD44 and CD24 can be transcriptionally activated by TGLI15 while this study 
shows TGLI1 to increase the CD44high/CD24low stem cell subpopulation. We speculate that 
TGLI1 may have increased the expression of nuclear CD24 but not cell-surface CD24 
expression. It has been recently discovered that biologically active CD24 is localized in the 
nucleus of cancer cells with low cell-surface CD24 expression. Importantly, they found that 
nuclear CD24 correlated with metastasis and that a nuclear CD24 gene signature was 
predictive of shortened survival for breast cancer patients33. In agreement with these 
findings, and the role of the TGLI1-CD24 signaling axis in promoting cancer migration and 
invasion5, 8 and metastasis (Figs. 1–2), other groups have shown that CD24-positive breast 
cancers are associated with tumor progression and poor survival34, 35. These results suggest 
that TGLI1 may increase nuclear CD24 expression but reduce cell-surface CD24 expression, 
and thereby contributes to breast CSCs and cancer metastasis. This possibility should be 
addressed in future studies.
Our results from three mouse models of breast cancer metastasis indicate that TGLI1 directs 
breast cancer metastasis to the brain and promotes breast cancer growth once in the brain. 
We also demonstrate TGLI1-positive CSCs strongly activate and interact with astrocytes in 
vitro and TGLI1-positive BCBM tumors activate astrocytes in vivo. The ability of TGLI1 to 
activate astrocytes should be investigated further. Apart from mediating breast CSCs to drive 
BCBM and activating astrocytes to alter the tumor microenvironment, another potential 
mechanism by which TGLI1 may mediate BCBM is through regulating exosomal 
microRNAs. Through secretion of exosomes, small extracellular vesicles containing growth 
factors, DNA, and microRNAs, primary tumors can prime distant organs for colonization of 
tumor cells36. Whether TGLI1-positive tumors secrete exosomal microRNAs to prime the 
brain for colonization remains to be investigated. Furthermore, results from our 
bioinformatic analysis implicate TGLI1 in facilitating lung and bone metastases 
(Supplementary Figs. 1 and 3). Using one cell line in our in vivo model, to overexpress 
TGLI1, we did not observe significant increase in lung (not shown) or bone metastases 
between vector, GLI1 or TGLI1 groups suggesting that TGLI1-positive breast cancers 
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preferentially metastasize to the brain. Similarly, TGLI1 knockdown in a brain trophic 
HER2-enriched cell line (SKBRM) did not lead to significant differences in lung and bone 
metastases. Future experiments using additional breast cancer cell lines, or genetically 
engineered mouse models, are needed to further define the impact of TGLI1 on breast 
cancer metastasis in the context of organ preference.
We found that TGLI1 overexpression transformed normal mammary epithelial cells 
resulting in increased mammosphere formation and anchorage-independent growth, key 
features of CSCs. This finding suggests TGLI1 may play an oncogenic role for mammary 
tumorigenesis. Future studies examining the role of TGLI1 in malignant transformation of 
normal mammary cells are needed. To meet this need, conditional transgenic mouse models 
may be established to allow for GLI1 gene knocked out and human TGLI1 gene knocked in. 
These floxed mice can then be crossed with mammary-specific Cre mice such as MMTV-cre 
mice. This transgenic mouse model will shed new light on the effects of TGLI1 on 
malignant transformation of mammary cells, breast tumor growth, and progression.
We identified OCT4 as a novel transcriptional target of TGLI1 in breast cancer cells (Fig. 6). 
OCT4 is an established stemness gene18. This novel TGLI1-OCT4 signaling axis represents 
a previously undescribed molecular mechanism underlying breast CSCs. Aberrant 
expression of OCT4 has been shown to promote breast cancer progression, chemoresistance, 
and metastasis, and to be associated with TNBCs37. In contrast, OCT4 overexpression 
resulted in decreased migration and invasion in vitro, as well as, decreased lung metastases 
in vivo38. Interestingly, a study demonstrated that OCT4 is expressed in adult stem cells and 
has been shown to mediate adult neural stem cell differentiation into dopaminergic 
neurons39. The important role of OCT4 in the adult brain may contribute to the observed 
preferential brain metastasis of TGLI1-positive breast cancers. Future studies are needed to 
address this possibility.
To fully understand the mechanism by which TGLI1 promotes breast CSCs, RNA-seq will 
be carried out in future to identify additional TGLI1-specific stemness genes. The current 
study identified OCT4 as a stemness gene that underlies TGLI1-mediated breast cancer 
stemness. This study also confirmed the existence of the TGLI1-CD44 signaling axis in 
breast cancer which was first discovered in GBM stem cells9. Based on these findings, 
TGLI1 may mediate breast CSCs through upregulating both OCT4 and CD44 plus 
additional genes. We demonstrate that TGLI1 outcompetes GLI1 for binding to the OCT4 
gene promoter which may contribute to the gain-of-function ability of TGLI1. We further 
uncovered that TGLI1, but not GLI1, upregulates GLI2 target genes including PDGFRβ, 
FGF19, and ARHGEF16. PDGFRβ is an important neuroprotective factor during brain 
injury and is associated with breast cancer brain metastasis and gastric cancer stem 
cells24, 40. FGF19, the human ortholog of FGF15, is essential for embryonic brain 
development41 and overexpression of FGF19 is implicated in breast cancer progression and 
metastasis42. ARHGEF16 was recently shown to promote glioma cell migration and 
proliferation22. Upregulation of these GLI2 target genes by TGLI1 further contributes to the 
aggressiveness of TGLI1. Future studies are needed to address how TGLI1 regulates GLI2 
target genes. One possibility for TGLI1’s gain-of-function ability is that TGLI1 may interact 
with other transcription factors to co-regulate gene expression. Another possibility is that 
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TGLI1 may bind to different consensus sites that GLI1 cannot bind. However, these 
possibilities will need to be thoroughly investigated in future studies.
In summary, our current study reports important findings on the novel functions of TGLI1 
and mechanisms contributing to BCBM, stem cells, reprogramming of tumor 
microenvironment via astrocyte activation, and radioresistance. The results from this study, 
together with previous studies, have further strengthened the rationale to further investigate 
the roles of TGLI1 in regulating exosomal microRNAs in the context of BCBM and 
mammary tumorigenesis, as well as, identify the mechanism that underlie the gain-of-
function transcriptional ability of TGLI1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: TGLI1 promotes brain metastasis of TNBC in an intracardiac injection metastasis 
mouse model.
A) Western blot analysis of isogenic MDA-MB-231 cell lines. B) IHC analysis of mammary 
fat pad MDA-MB-231 xenografts from female athymic mice and primary breast cancer 
patient samples using GLI1- and TGLI1-selective antibodies. C) Expression of TGLI1 in 
MDA-MB-231-TGLI1 MFP xenograft was similar to that found in two breast cancer PDXs. 
Western blots using the TGLI1-specific antibody were conducted. D) Bioluminescent 
images of female athymic mice 22 days post intracardiac injection of isogenic MDA-
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MB-231 cell lines. Dorsal and brain views are shown. Twelve mice per group were used. 
Two mice in vector and one mouse in TGLI1 groups died during quantified. G) Tumor foci 
within mouse brains were determined via ex vivo brain imaging. H) Representative ex vivo 
IVIS images of brain and bone are shown. Student’s t-test was used to compute p-values for 
panels E and F.
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Figure 2: TGLI1 promotes TNBC growth in mouse brain in an intracranial injection mouse 
model.
Isogenic MDA-MB-231 lines were implanted into mouse brain and imaged weekly via an 
IVIS imager. Eight mice per group were used in which one mouse in the GLI1 group died of 
ketamine overdose. A) IVIS images of female athymic mice 3 weeks post intracranial 
implantation. B) Incidence of BCBM formation in each group. *, + indicates p< 0.05 
between vector and TGLI1 or GLI1 and TGLI1, respectively. Fisher’s Exact Test was used. 
C) Growth curve for intracranial tumors. * indicates p< 0.05. D) Representative mouse 
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brains showing TGLI1 BCBM being more vascularized. E) Analysis of BCBM for GLI1/
TGLI1 expression (IHC), invasiveness (H&E), microvessel density (CD31 IHC) and 
proliferation index (Ki-67 IHC). F) Microvessel density. G) Proliferation Index. Student’s t-
test was used to compute p-values for panels F and G.
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Figure 3: TGLI1 activation is enriched in HER2-enriched breast cancer and TNBC, and 
associated with poor MFS; TGLI1 expression is increased in lymph node metastases and BCBM 
specimens.
A-B) Bioinformatic analysis of GEO datasets (GSE12276/2034/2603/5327/14020; Panel A) 
comprised of 710 breast tumors and TCGA dataset (Panel B) comprised of 1,136 breast 
tumors for tGAS-6 enrichment and GLI1/TGLI1 mRNA expression. C-D) Kaplan-Meier 
curves showing the correlations between tGAS-6 or GLI1/TGLI1 mRNA expression with 
overall MFS (Panel C) and brain MFS (Panel D). Only 672 out of 710 patients in the GEO 
cohort had survival data. Log rank test was used to compute p-values. E-K) IHC analysis of 
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patient specimens using TGLI1 and GLI1 specific antibodies developed in our laboratory. 
Panel E shows the expression of GLI1 and TGLI1 in primary breast tumors that are either 
lymph node-negative, LN(−), or lymph node-positive, LN(+). Panels F-G, expression levels 
of GLI1 and TGLI1 in matched primary breast cancers and lymph node metastases (N=47). 
Panel H shows that TGLI1 expression is higher than GLI1 in LN(+) breast cancer in a pair-
wised analysis (N=57). Panel I shows GLI1 and TGLI1 expression in 56 primary breast 
tumors and 37 BCBM specimens. Panel J contains a pairwise analysis of 37 BCBM for 
GLI1 and TGLI1 expression; Panel K shows representative primary breast cancer and 
BCBM samples immunostained for GLI1 and TGLI1. Student’s t-test was used to compute 
p-values.
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Figure 4: TGLI1 contributes to BCBM radioresistance.
A) Expression levels of TGLI1 and GLI1 in SKBRM cells treated with 0, 2, or 5 Gy of 
radiation. TGLI1 and GLI1 mRNA expression was determined 30 minutes after irradiation. 
B-C) Relative TGLI1 or GLI1 mRNA expression in radiosensitive and radioresistant brain-
tropic breast cancer cell lines. D) TGLI1 mRNA was expressed at higher levels in SKBRM-
RR mammospheres than SKBRM mammospheres. GLI1 expression was significantly 
decreased in the radioresistant mammospheres. E-F) SKBRM and SKBRM-RR cells 
transfected with control, GLI1-, or TGLI1-vector were irradiated (2 Gy) and subjected to 
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mammosphere formation assay. G-H) IHC staining of 20 radiosensitive BCBM tumors and 
16 radioresistant BCBM tumors using GLI1 and TGLI1 specific antibodies developed in our 
laboratory. I) Representative immunostained BCBM specimens. *Indicates significant 
difference (p<0.05). Student’s t-test was used to compute p-values.
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Figure 5: TGLI1 promotes breast cancer stem cells and TGLI1-positive stem cells activate 
human astrocytes.
A) Expression of GLI1 and TGLI1 mRNA in a two breast cancer cell lines grown in 
monolayer or mammospheres. Regular RT-PCR was conducted. MS, mammosphere. ML, 
monolayer. B) GLI1 and TGLI1 mRNA expression in SKBRM MS relative to ML, as 
determined by qRT-PCR. C) TGLI1 overexpression in MDA-MB-231 cells led to increased 
stem cell population defined by CD44high/CD24low as determined by FACS. D-F) TGLI1 
ectopic expression enhanced the mammosphere-forming ability of BT20 cells. Panel D, 
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average number of mammospheres. Panel E, average size of mammospheres. Panel F, 
representative images of mammospheres. G-I) TGLI1 ectopic expression enhanced the 
mammosphere-forming ability of SKBRM cells. Panel G, average number of 
mammospheres. Panel H, average size of mammospheres. Panel I, representative images of 
mammospheres. J-K) GFAP expression is increased in human astrocytes upon stimulation 
with conditioned medium (CM) from TGLI1-positive mammospheres. Isogenic SKBRM 
cells grown in monolayer or mammospheres were used. Panel J, representative images. 
Panel K, percent GFAP positive cells. L) Co-culture of human astrocytes (GFP-tagged) with 
isogenic SKBRM cells (RFP-tagged) under the sphere-forming condition. M-N) Analysis of 
isogenic MDA-MB-231 intracranial tumors for activated astrocytes (GFAP IHC). M) 
Representative images. N) Quantified number of astrocytes per area of tumor. Student’s t-
test was used to determine p-values.
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Figure 6: TGLI1 upregulates stemness genes in breast cancer cells; Eight-gene TGLI1 activation 
signature (tGAS-8) is predictive of breast cancer metastasis and radioresistance.
A-C) TGLI1 upregulates expression of four stemness genes in two breast cancer cell lines of 
different subtypes. Quantitative RT-PCR was performed using transfected MDA-MB-231and 
SKBRM cells. D) Protein levels of all four stemness genes were enhanced by TGLI1 in 
SKBRM cells. Western blotting was conducted. E&F) SKBR3 cells were transiently 
transfected with promoter luciferase reporters and vector, GLI1 or TGLI1 plasmids, 
stimulated with SHH ligand (100 ng/mL) for 4 hrs and promoter transactivation was 
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measured by luciferase assay. E) Relative transactivation of the Nanog promoter by GLI1 or 
TGLI1. F) Relative transactivation of the SOX2 promoter by GLI1 or TGLI1. G) Relative 
binding of GLI1 or TGLI1 to the CD44 promoter as measured by the ChIP assay using 
transfected SKBR3 cells. H) Relative transactivation of the CD44 promoter by GLI1 or 
TGLI1 in SKBR3 cells. I) Relative binding of GLI1 or TGLI1 to the OCT4 promoter in 
SKBR3 cells as determined by the ChIP assay. qPCR was performed using primers spanning 
the OCT4 gene promoter. J) Relative transactivation of the OCT4 promoter by GLI1 or 
TGLI1 in SKBR3 cells as determined by the luciferase reporter assay. K) Relative binding 
of GLI1 or TGLI1 to the OCT4 promoter in MDA-MB-231 cells with dual overexpression 
of GLI1 and TGLI1 as determined by the ChIP assay using GLI1-specific and TGLI1-
specific antibodies developed and validated in our laboratory. Student’s t-test was used to 
determine p-values. L-M) The same GEO cohort of 710 breast tumors from Figure 3 was 
used. L) Metastatic breast tumors had higher tGAS-8 than non-metastatic counterparts. M) 
Patients with high tGAS-8 have a shortened overall MFS and brain MFS compared to those 
with low tGAS-8. N) GSEA that determined whether breast tumors with high tGAS-8 or 
high TGLI1/GLI1 mRNA were enriched for breast cancer brain metastasis signature. NES, 
normalized enrichment score.
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Figure 7: Knockdown of TGLI1 suppresses breast cancer stem cells in vitro and reduces BCBM 
in vivo.
Antisense oligonucleotides (AS-ON) were used to knockdown TGLI1. A-B) Selective 
knockdown of TGLI1 as indicated by qRT-PCR and effects of TGLI1 knockdown on 
mammosphere formation in A) BT-20 cells and B) SKBRM cells. C) Decreased expression 
of OCT4 and SOX2 with TGLI1 knockdown. Quantitative RT-PCR was performed using 
transfected SKBRM cells. In Panels D-G, athymic mice were inoculated with SKBRM cells 
transfected with negative control oligos or TGLI1-AS-ON through intracardiac injections 
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(12 mice per group). D) Bioluminescent images of female athymic mice 25 days post 
intracardiac injection of transfected SKBRM cells. Dorsal and brain views are shown. E) 
Representative ex vivo IVIS images of brain and bone are shown. F) Brain ex vivo 
bioluminescence was quantified. G) Bone ex vivo bioluminescence was quantified. 
Student’s t-test was used to compute p-values.
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